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In membranes of undifferentiated neuroblastoma x glioma hybrid cell line NGlOS-15, the apparent specific binding of pH]yohimbine measured 
in the presence of 1 PM noradrenaline, was increased substantially by the pmsencc of the poorly hydrolysed analogue of GTP, guanylyl-imidodi- 
phosphate (GpplNHlp) or by preincubation of membranes with antibodies against he C-terminal decapeptide of the a subunit of the G-protein 
G,2. Such an effect was not produced by antibodies against the equivalent region of G& Gi3a or Gp or from non-immune serum. By contrast, 
total specific binding of PHlyohimbine was not modified by co-incubation with Gpp(NHlp or by preincubation with the antibodies from any of 
the anti-G protein antisera. These results demonstrate a direct interaction of the %B adrenergic receptor of NGl08-15 cells with G,2. 
%B Adrenergic receptor; Guanine nucleotide binding protein; Anti-peptide antiserum; Pertussis toxin 
1. INTRODUCTION 
The neuroblastoma x glioma hybrid cell line, NG- 
108-15, is widely used as a model system to study 
transmembrane signalling cascades [ 1,2]. These cells ex- 
press a considerable range of receptors which inhibit 
adenylate cyclase including those for 0~2 adrenergic, 6 
opioid and muscarinic ligands [ 11. Receptor-mediated 
inhibition of adenylate cyclase is transduced via the per- 
tussis toxin-sensitive G-protein ‘Gi’ [3]. However, the 
expression of three distinct pertussis toxin-sensitive 
G-proteins, Gr2, Gi3 and G,, by NGlOS-15 cells has 
been demonstrated both by pertussis toxin-catalysed 
[32P]ADP-ribosylation [4] and by immunoblotting with 
specific antipeptide antisera able to discriminate be- 
tween these G-proteins [4] and hence it is unclear which 
of these G-proteins functions as ‘Gi’. 
In this report we assess this question in membranes of 
undifferentiated NG108-15 cells. We use a series of an- 
tisera directed against synthetic peptides which corres- 
pond to the C-terminal decapeptides of the (Y subunits 
of the individual G-proteins expressed by these cells to 
attempt to uncouple the CQB adrenergic receptor from 
the G-protein signalling system. Uncoupling of receptor 
and G-protein is known to reduce the affinity of 
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ligand causing 50% inhibition of specific receptor binding 
agonists, but not antagonists, for receptors [5]. Thus, 
when measuring displacement of specific binding of an 
[3H]antagonist by an agonist, uncoupling and hence a 
reduction in agonist affinity will result in an increase in 
specific [‘HIantagonist binding. Such effects were 
observed when either a poorly hydrolysed analogue of 
GTP, Gpp[NH]p, or an IgG fraction from an an- 
tiserum (AS7) able to identify only Gt2o in these cells 
was used. No such effect was noted with the use of IgG 
fractions derived from antisera against the equivalent 
regions of Gr3o,Goo or Gsar. These data demonstrate a
direct interaction of Gi2 with the crzB adrenergic recep- 
tor in NG 108- 15 cells and provide a methodology which 
should be applicable to any receptor which interacts 
with a G-protein(s). 
2. MATERIALS AND METHODS 
2.1. Materials 
[3H]yohimbine (79.5 Ci/mmol) was purchased from New England 
Nuclear/DuPont. Oxymetaxoline, prazosin and noradrenaline were 
from Sigma. All reagents for tissue culture were purchased from Gib- 
co (Paisley, Scotland). 
2.2. Cell culture 
Neuroblastoma x glioma hybrid, NG108-15, cells were grown in 
tissue culture as previously described [a]. In a number of cases the 
cells were treated with pertussis toxin (Porton Products, Porton 
Down, UK) (100 t&ml, 16 h). Cells were harvested when some 80% 
confluent and membrane fractions prepared in 10 mM TrisHCl. 0.1 
mM EDTA, pH 7.5 (buffer A) as in [a]. Membranes were stored at 
- 70°C before use. 
2.3. Immunological studies 
The generation and specificities of the various antisera used in this 
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Antiserum 
AS1 
OCl 
13B 
CSl 
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Table I 
Generation and specificities of anti-G-protein antisera 
Peptide employed Corresponding G-protein 
sequence 
KENLKDCGLF Transducin OL 341-350 
ANNLRGCGLY G& 345-354 
KNNLKECGLY Gi3o 345-354 
RMHLRQYELL G.a 385-394 
September 1990 
Antiserum identifies 
Transducin, Gil, Gi2 
G0 
Gr3 
G* 
study are defined in Table I. Each antiserum was produced in New 
Zealand White rabbit using a conjugate of a synthetic peptide and 
keyhole limpet haemocyanin (Calbiochem) as antigen. The details of 
this process have previously been recorded [7]. Details of the im- 
munoblotting protocols and use of these antisera to study functional 
interactions of receptors and G-proteins have previously been record- 
ed 141. 
2.4. Binding experiments 
Were performed at 25’C for 30 minutes in 10 mM Tris HCI, 50 mM 
sucrose, 20 mM MgCls, pH 7.5 (Buffer B). In saturation experiments 
using [3H]yohimbine the concentration of ligand was varied between 
0.5 and 20 nM. Non-specific binding was defined in all cases by 
parallel assays containing 100 pM noradrenaline. Non-specific bind- 
ing increased with [“Hlligand concentration i  a linear manner. Bind- 
ing experiments were terminated by rapid filtration through What- 
man GF/C filters followed by three washes of the filter with ice cold 
buffer B (5 ml). In a number of experiments, the membranes were pre- 
incubated with IgG fractions derived from either normal rabbit serum 
of from a series of polyclonal anti-peptide antisera directed against 
the C-terminal decapeptides of the (Y subunit of the G-proteins ex- 
pressed by NG108-15 cells (see below for production of the IgG frac- 
tions) for 60 min at 30°C before performing the binding assay. We 
have previously noted that such treatment will allow the uncoupling 
of receptors from G-proteins [4]. 
2.5. Generation of IgG fractions from anti-G-protein antisera 
A column of protein A-sepharose 4B (Pharmacia) (0.5 ml) was 
equilibrated with 1.5 M glycine pH 8.9, 3 M NaCl (buffer C). 5 ml of 
antiserum in buffer C was added to the column and allowed to 
equilibrate with gentle mixing. The column was washed with buffer C 
until the eluate had A=0 = 0.0 and then eluted with 100 mM citric 
acid, pH 4.0 into 2 M Tris/HCl, pH 7.5. The eluted IgG fractions 
were dialysed overnight against 1000 volumes of buffer A. then 
lyophilixed and reconstituted with buffer A prior to use. 
3. RESULTS 
Saturation binding isotherms in which [3H]yohim- 
bine was used as a ligand for the cy2 adrenergic receptor 
expressed by neuroblastoma x glioma hybrid, NG108- 
15, cells demonstrated an apparent single population of 
receptor sites for which the dissociation constant of 
[‘Hlyohimbine was some 2.5 f 0.6 nM (mean f SD, 
n = 3) and maximal capacity some 80 f 14 fmol/mg 
membrane protein (mean f SD, n = 3) (results not 
shown). Displacement of specific [‘Hlyohimbine bind- 
ing from this site was achieved with high affinity by 
both prazosin (I& corrected for receptor occupancy = 
33 f 5 nM) and oxymetazoline (I& corrected for 
receptor occupancy = 24 f 10 nM) (means f S.D., n = 
3) which suggests that the receptor is of the ar2B 
subclass. Specific [“Hlyohimbine binding was displaced 
by noradrenaline (ICSO corrected for receptor occupan- 
cy = 0.5 PM) and the effectiveness of noradrenaline to 
inhibit specific [‘Hlyohimbine binding was reduced 
some 5-fold (I& corrected for receptor occupancy = 
2.6 PM) when the experiment was performed in the 
presence of Gpp[NH]p (100 FM). By immunoblotting 
membrane fractions of NG108-15 cells with a series of 
antipeptide antisera directed against the extreme C- 
terminal region of the various G-proteins we 
demonstrated the expression of the (r subunits of each 
of Gi2,Gi3,Go and G,, as we have recorded previously 
[4]. However, Grlo is either not expressed or its expres- 
sion is so limited that it is below current levels of detec- 
tion [4]. 
The apparent specific binding of a single concentra- 
tion of [‘Hlyohimbine (2 nM) in the presence of 1 PM 
noradrenaline was, in the experiment displayed in Fig. 
1, 28% of that in the absence of noradrenaline. This 
was increased to 75% of the total specific binding when 
the experiment was performed in the presence of 
GPP[NH]p (100 PM) (Fig. 1). This difference in specific 
binding of [‘Hlyohimbine when the experiment was 
performed in either the presence or absence of 
GPP[NH]p thus provides a measure of receptor- 
interaction with the G-protein population of these 
membranes. 
When membranes from NG108-15 cells were prein- 
cubated with an IgG fraction isolated from antiserum 
AS7, which in these cells identifies only Gi2 [4], the level 
of specific binding of [3H]yohimbine in the presence of 
1 PM noradrenaline was similar to that when the bind- 
ing assay was performed in the presence of Gpp[NH]p 
(70% of total specific binding) (Fig. 1). An IgG fraction 
from normal rabbit serum was unable to mimic this ef- 
fect of antiserum AS7 (Fig. 1). By contrast, incubation 
of membranes with the IgG fraction from antiserum 
AS7 or in the presence of Gpp[NH]p had no effect on 
the total specific binding of [‘Hlyohimbine (Fig. 2). 
Following preincubation of cells with pertussis toxin 
(100 ng/ml, 16 h) and the preparation of membranes, 
specific [‘Hlyohimbine binding in the presence of 1 pM 
noradrenaline was significantly greater (67 f 3% of 
total specific binding, mean f S.D. (n = 4)) than in 
membranes derived from untreated cells (40 f 4%) 
(Table II). Neither Gpp[NH]p (100 PM] or preincuba- 
tion with the IgG fraction from antiserum AS7 was able 
to modify the extent of displacement of specific 
[‘Hlyohimbine binding by 1 PM noradrenaline from 
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ABCDEF 
Treatment 
Fig. 1. Antibodies from antiserum AS7 but not from antisera directed 
against he C-terminal region of other G-proteins mimic Gpp[NH]p in 
causing an increase in the apparent specific binding of [“Hlyohimbine 
in the presence of 1 pM noradrenaline to membranes of NGIOS-15 
cells. Membranes (100 pg) from undifferentiated NGlOS-15 cells were 
incubated with IgG fractions (amount equivalent o a 1:50 dilution of 
the crude antiserum) from either normal rabbit serum (A,B), 
antiserum AS7 (C), antiserum OCl (D), antiserum CSl (B) or 
antiserum 13B (P) for 60 min at 30°C. The specific binding of 
[‘Hlyohimbine (2 nM) in the presence of 1 PM noradrenaline was then 
assessed as in section 2. During the binding assay Gpp[NH]p (100~) 
was also included in (B). In these experiments 100% [3H]yohimbine 
specific binding was 24.0 fmol/mg membrane protein. Bars represent 
means rt SD (n = 4). 
membranes from pertussis toxin-pretreated cells in 
which the receptor is uncoupled from its G-protein 
(Table 2) in contrast to the effects of these agents in 
membranes from untreated cells (Fig. 1). 
0 
A B C 0 
Fig. 2. Lack of effect of agents which uncouple (~2 receptors from the 
G-protein signalling cascade on the total specific binding of 
[‘Hlyohimbine. Membranes (100 pg) from undifferentiated 
NGlOS-15 cells were preincubated as in Fig. 3 with either no additions 
(A,D), an IgG fraction from antiserum AS7 (B) or an equivalent IgG 
fraction from normal rabbit serum (C). The specific binding of 
[‘Hlyohimbine (2 nM) was then assessed as in section 2. During the 
binding assay Gpp[NH)p was also included in (D). In this experiment 
100% specific binding was 23.9 fmol/mg protein. Bars represent 
means f SD (n = 4). 
To assess the potential interactions of the ar2 
adrenergic receptor with other G-proteins, membranes 
of untreated NGlOS-15 cells were preincubated with 
IgG fractions isolated from antisera directed against he 
C-terminal decapeptides of each of the other G-proteins 
expressed by these cells (G,cr (OCl), Gt3o (13B) or Gscv 
(CSl)). None of these antibody preparations altered 
specific [‘Hlyohimbine binding, whether measured in 
the presence or absence of 1 PM noradrenaline (Fig. 3 
and results not shown) although all can im- 
munoprecipitate the relevant G-proteins from mem- 
branes of these cells (results not shown). 
4. DISCUSSION 
In undifferentiated neuroblastoma x glioma hybrid, 
Table II 
Gpp[NH]p and antibodies from antiserum AS7 have no effect on the specific binding of [‘Hlyohimbine in the presence of 1 PM noradrenaline 
in membranes from NGlOS-15 cells which have been treated with pertussin toxin 
Treatment [3H]yohimbine binding in the presence of 1 PM noradrenaline (% 
total specific) 
Untreated cells: preincubation with non-immune IgG 40*4 
Pertussis toxin pretreated cells: preincubation with non-immune IgG 67 f 3 
Pertussis toxin pretreated cells: preincubation with non-immune IgG 
Gpp[NH]p in binding assay 74 f 12 
Pertussis toxin pretreated cells: preincubation with IgG form 
antiserum AS1 67 f 2 
NGlOS-15 cells were treated with either pertussis toxin (100 ng/ml, 16 h) or with vehicle and membranes prepared. Binding assays were performed 
as in section 2 in either the presence or absence of Gpp[NH]p (100 PM) following preincubation with IgG fractions (amounts equivalent o a 1:50 
dilution of the serum) isolated from either antiserum AS7 or from non-immune serum. Numbers represent means zt SD (n = 4). 
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NG108-15, cells an (r2 adrenergic receptor is able to 
mediate inhibition of adenylate cyclase [8]. Pretreat- 
ment of the cells with pertussis toxin attenuates 
adrenergic inhibition of adenylate cyclase by preventing 
productive contact between receptor and its G-protein 
[5]. This indicates that receptor-mediated inhibition of 
adenylate cyclase is transduced by one or more 
members of the family of G-proteins which are 
substrates for mono-ADP-ribosylation catalysed by 
pertussis toxin. The primary sequence of each of these 
pertussis toxin sensitive G-proteins has a cysteine 
residue located 4 amino acids from the C-terminus and 
it is this amino acid which acts as the acceptor for per- 
tussis toxin-catalysed ADP-ribosylation [9]. These 
observations provided the first evidence that the C- 
terminal region of G-proteins was likely to represent a 
key site for contact between receptors and G-proteins. 
We reasoned that antisera directed against the C- 
terminal region of the (Y subunit of various G-proteins 
might be able to uncouple receptors and G-proteins and 
would thus provide information of the specificity or 
otherwise of receptor-G-protein coupling in native 
membranes and in whole cells. We have generated a 
series of antipeptide antisera directed against the C- 
terminal decapeptides of various G-proteins and have 
previously characterized their specificity for the in- 
dividual G-proteins in immunoblots and im- 
munoprecipitation protocols [7,10,1 l-l 31. We, and 
others, have been able to use such antisera to interfere 
with the interaction of receptors with each of G, [14] 
and Nair, Parikh, Milligan and Pate1 (submitted) Gi2 
[4,6,15], rod transducin [16] and G, [17] by measuring 
the attenuation of either receptor-driven high affinity 
GTPase activity or of the activity of the effector system. 
For technical reasons it is often difficult, however, to 
measure receptor-driven increases in high affinity 
GTPase activity [ 181. Moreover, regulation of second 
messenger production is removed both spatially and 
temporally from the initial contact between receptor 
and G-protein and hence might be subject to extraneous 
influences. To combat such problems we have now 
developed an assay which is potentially amenable to all 
receptors which interact with G-proteins and which 
should allow assessment of the specificity (or otherwise) 
of receptor-G-protein interaction. This assay relies on 
the reduction in binding affinity for agonists but not an- 
tagonists, which has been well established to occur 
when receptor and G-protein become dissociated from 
one another [18]. 
In membranes of undifferentiated NG108-15 cells, in 
the absence of guanine nucleotides, 1 gM noradrenaline 
displaced some 70% of specifically bound antagonist 
([3H]yohimbine (2 nM). However, when the poorly 
hydrolysed GTP analogue, Gpp[NH]p (100 PM) was 
also present only 30% of the [‘Hlyohimbine was 
displaced by 1 pM noradrenaline. We then assessed 
whether antipeptide ant&era to the various G-proteins 
which are expressed by NG108-15 cells would be able to 
mimic the effect of Gpp[NH]p. Following preincuba- 
tion of membranes of NGlOS-15 cells with antibodies 
derived from antiserum AS7, exactly the same increase 
of specific [3H]yohimbine binding in the presence of 
noradrenaline (1 PM) was observed as with Gpp[NH]p 
(Fig. 1). Moreover, like Gpp[NH]p, the IgG fraction 
from antiserum AS7 had no effect on total specific 
t3H]yohimbine binding (Fig. 2). By contrast, the IgG 
fractions derived from normal rabbit serum and from 
each of antisera 13B (anti-Gdcr), OCl (anti-G& and 
CSl (anti-G,cr) had no effect on either total specific bin- 
ding of [‘Hlyohimbine or specific binding of this ligand 
in the presence of 1 PM noradrenaline. 
Antiserum AS7 was produced against the C-terminal 
decapeptide of rod transducin but identifies both Gilo 
and Gi2a as well as transducin [7]. This reflects the fact 
that the C-terminal decapeptides of Gil and Gi2 are 
identical and differ in but a single amino acid from that 
of transducin. As such this antiserum cannot provide a 
selective probe for functional studies in cells or tissues 
in which more than one of these three polypeptides is 
expressed. The expression of transducin is limited to 
photoreceptor containing tissues and we have 
demonstrated previously that Gil is not expressed by 
NGlOS-15 cells [4]. This antiserum can therefore be us- 
ed as a specific probe for Gi2 in these cells. Treatment 
of membranes of undifferentiated NGlOS-15 cells with 
antibodies from antiserum AS7, but not with equivalent 
antibodies which identify the other G-proteins present 
in the plasma membrane of these cells, converted the (r2 
adrenergic receptor to a form which displayed reduced 
affinity for agonist but not antagonist. Hence we are 
able to conclude that the 012 adrenergic receptor in- 
teracts directly with Gi2. 
We have previously noted that (r2 adrenergic inhibi- 
tion of Ca2 + currents in NG 108- 15 cells is attenuated by 
intracellular injection of antibodies from antiserum 
OCl (anti-G,,cr) and not by antibodies from either an- 
tiserum AS7 (anti-Gi2cr) or antiserum 13B (anti-Gdcr) 
[ 171. These data provided clear evidence that G, func- 
tions to regulate receptor-control of voltage-sensitive 
Ca2 + channels in NGlOS-15 cells [ 171, a proposal which 
had originally been suggested by reconstitution ex- 
periments by Schultz and co-workers [19]. We must 
therefore address why it appears in the experiments 
reported herein, that ar2 receptors interact exclusively 
with Gi2. The major difference in the experiments 
described here and those employing elec- 
trophysiological approaches is the state of the 
NG108-15 cells. For electrophysiological experimenta- 
tion it is routine to chemically ‘differentiate’ the cells by 
treating them for a number of days with one of a range 
of agents which elevate intracellular CAMP levels [ 11. 
During such ‘differentiation’ the cells withdraw from 
the cell cycle and become considerable more electrically 
excitable [l]. In parellel with the ‘differentiation’, 
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cellular levels of G, increase markedly [l 11, although 
there is no reason to believe that these two phenomena 
are other than co-incidental. Dependent upon the agent 
employed to ‘differentiate’ the cells, levels of Gi2 may 
fall considerably or remain relatively unchanged [20, 
Mullaney, Frenz and Milligan, unpublished observa- 
tions]. In the undifferentiated state, G, appears to 
represent only some 5-10% of the total population of 
pertussis toxin sensitive G-proteins in the cells [17]. By 
contrast, in the ‘differentiated’ cells this G-protein 
represents between 25-50% of the total pertussis toxin- 
sensitive G-proteins. The two states are therefore not 
highly comparable. It is thus possible that the cr2 
adrenergic receptor is physically capable of interacting 
with two distinct G-proteins and that the relative pro- 
portions of these at the membrane will determine the in- 
tegration of effector regulation following agonist ac- 
tivation of the receptor [17]. 
In previous studies we have demonstrated that the 
binding of a [3H]agonist to a 6 opioid receptor in 
NG108-I5 cell membranes is reduced in affinity but not 
maximal capacity by pretreatment of membranes from 
the cells with antibodies from antiserum AS7 [4]. Here 
we observe an alteration in apparent specific receptor 
binding of a [‘HIantagonist produced by this same anti- 
body. This effect is based upon competition for the 
receptor between the [‘HIantagonist and a fixed con- 
centration of a receptor agonist. We propose that such 
approaches hould be useful to study the specificity of 
interactions of any receptor with a G-protein. 
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